Coagulopathies and arterial stroke

Journal of Neuro-Ophthalmology

Volumn 23, Issue 1, 2003, Pages 63-71

  Moster, Mark L ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; PHOSPHOLIPID ANTIBODY; PLASMINOGEN; PROTEIN C; PROTEIN S; PROTHROMBIN;

ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN III DEFICIENCY; ARTERY THROMBOSIS; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; DYSFIBRINOGENEMIA; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HYPERHOMOCYSTEINEMIA; PREVALENCE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK ASSESSMENT; SICKLE CELL ANEMIA; STROKE; THROMBOSIS;

ANEMIA, SICKLE CELL; ANTIPHOSPHOLIPID SYNDROME; BLOOD PROTEIN DISORDERS; CEREBROVASCULAR ACCIDENT; DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR V; FIBRINOGENS, ABNORMAL; HUMANS; HYPERHOMOCYSTEINEMIA; PLASMINOGEN; PROTHROMBIN;

EID: 0037337239     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041327-200303000-00012     Document Type: Conference Paper

References (118)

1. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999;340:1555-64.
2. Hirsh J, Colman RW, Marder VJ, et al. Overview of thrombosis and its treatment. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2001:1071-84.
3. Marder VJ, Matei DE. Hereditary and acquired thrombophilic syndromes. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2001:1243-75.
4. Biousse V. Coagulation abnormalities and their neuroophthalmologic manifestations. Curr Opin Ophthalmol 1999;10: 382-93.
5. Bushnell CD, Goldstein LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 2000;31:3067-78.
6. Schafer AI. Thrombotic disorders: hypercoagulable states. In: Goldman L, Bennett JC eds. Cecil Textbook of Medicine, vol 1, 21st edn. Philadelphia: W.B. Saunders, 2000:1-13.
7. De Lucia D, d'Alessio D, Pezzella S, et al: A hypercoagulable state in activated protein C resistant patients with ischemic stroke. Int J Clin Lab Res 1998;28:74-5.
8. Camerlingo M, Finazzi G, Casto L, et al. Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology 1991;41:1371-3.
9. Martinez HR, Rangel-Guerra RA, Marfil LJ. Ischemic stroke due to deficiency of coagulation inhibitors. Report of 10 young adults. Stroke 1993;24:19-25.
10. Uysal S, Anlar B, Altay C, et al. Role of protein C in childhood cerebrovascular occlusive accidents. Eur J Pediatrics 1989;149: 216-8.
11. Israels SJ, Seshia SS. Childhood stroke associated with protein C or S deficiency. J Pediatrics 1987;111:562-4.
12. Simioni P, Zanardi S, Saracino A, et al. Occurrence of arterial thrombosis in a cohort of patients with hereditary deficiency of clotting inhibitors. J Med 1992;23:61-74.
13. Sakata T, Kario K, Katayama Y, et al. Analysis of 45 episodes of arterial occlusive disease in Japanese patients with congenital protein C deficiency. Thromb Res 1999;94:69-78.
14. Adams HP, Kappelle LJ, Biller J, et al. Ischemic stroke in young adults. Experience in 329 patients enrolled in the Iowa Registry of stroke in young adults. Arch Neurol 1995;52:491-5.
15. Girolami A, Simioni P, Lazzaro AR. Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): a family study. Thromb Haemostasis 1989;61:144-7.
16. Barinagarrementeria F, Brito C, Izaguirre R, et al. Progressive intracranial occlusive disease associated with deficiency of protein S: report of two cases. Stroke 1993;24:1752-6.
17. Lagosky S, Witten CM. A case of cerebral infarction in association with free protein S deficiency and oral contraceptive use. Arch Phys Med 1993;74:98-100.
18. Simioni P, Battistella PA, Drigo P, et al. Childhood stroke associated with familial protein S deficiency. Brain Dev 1994;16:241-5.
19. Barinagarrementeria F, Cantu-Brito C, De La Pena A, et al. Prothrombotic states in young people with idiopathic stroke: a prospective study. Stroke 1994;25:287-90.
20. Sacco RL, Owen J, Mohr JP, et al. Free protein S deficiency: a possible association with cerebrovascular occlusion. Stroke 1989;20: 1657-61.
21. Green D, Otoya J, Oriba H, et al. Protein S deficiency in middleaged women with stroke. Neurology 1992;42:1029-233.
22. Vrethem M, Dahle C, Lindahl T. Association between deficiency of free protein S and anticardiolipin antibodies in patients ≤ 65 years of age with acute ischemic stroke and TIA. Eur J Neurol 1998;5: 491-7.
23. Kristensen B, Malm J, Carlberg B, et al. Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in Northern Sweden. Stroke 1997;28:1702-9.
24. Mayer SA, Sacco RL, Hurlet-Jensen A, et al. Free protein S deficiency in acute ischemic stroke: a case-controlled study. Stroke 1993;24:224-7.
25. Johnson EJ, Prentice CR, Parapia LA. Premature arterial disease associated with familial antithrombin III deficiency. Thromb Haemostasis 1990;63:13-5.
26. Arima T, Motomura M, Nishiura Y, et al. Cerebral infarction in a heterozygote with variant antithrombin III. Stroke 1992;23:1822-5.
27. Simioni P, de Ronde H, Prandoni P, et al. Ischemic stroke in young patients with activated protein C resistance: a report of three cases belonging to three different kindreds. Stroke 1995;26:885-90.
28. Lalouschek W, Aull S, Serles W, et al. C677T MTHFR mutation and factor V leiden mutation in patients with TIA/minor stroke: a case-control study. Thromb Res 1999;93:61-9.
29. Nabavi DG, Junker R, Wolff E, et al. Prevalence of factor V Leiden mutation in young adults with cerebral ischemia: a case-control study on 225 patients. J Neurol 1998;245:653-8.
30. Albucher JF, Guiraud-Chaumeil B, Chollet F, et al. Frequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke. Stroke 1996;27:766-7.
31. Landi G, Cella E, Martinelli I, et al. Arg506Gln factor V mutation and cerebral ischemia in the young. Stroke 1996;27:1697-8.
32. Margaglione M, D'Andrea G, Giuliani N, et al. Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden, Arteriosclerosis Thromb Vasc Biol 1999;19:1751-6.
33. DeLucia D, Cerbone AM, Belli A, et al. Resistance to activated protein C in adults with a history of juvenile transient ischemic attacks. Thromb Haemost 1996;76:627-8.
34. Mohanty S, Saxena R, Behari M. Activated protein C (APC) resistance in young stroke patients. Thromb Haemost 1999;81:465-6.
35. Halbmayer WM, Haushofer A, Schon R, et al. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinolysis 1994;5:51-7.
36. Zenz W, Bodo Z, Plotho J, et al. Factor V leiden and prothrombin gene G 20210 A variant in children with ischemic stroke. Thromb Haemost 1998;80:763-6.
37. Nowak-Gottl U, Koch HG, Aschka I, et al. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol 1996;92:992-8.
38. Eskandri MK, Bontempo FA, Hassett AC, et al. Arterial thromboembolic events in patients with the factor V leiden mutation. Am J Surg 1998;176:122-5.
39. Bontempo FA, Hassett AC, Faruki H, et al. The factor V leiden mutation: spectrum of thrombotic events and laboratory evaluation. J Vasc Surg 1997;25:271-5.
40. Dacosta A, Tardy-Poncet B, Isaaz K, et al. Prevalence of factor V leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries. Heart 1998;80:338-40.
41. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
42. Cushman M, Rosendaal FR, Psaty BM, et al. Factor V leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998;79:912-5.
43. Kontula L, Ylikorkala A, Miettinen H, et al. Arg506Gln factor V mutation (factor V leiden) in patients with ischemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995;73:558-60.
44. Iniesta JA, Corral J, Fernandez-Pardo J, et al. Factor-V (Arg 506 → Gln) mutation in ischemic cerebrovascular disease. Haemostasis 1997;27:105-11.
45. Sanchez J, Roman J, De La Torre MJ, et al. Low prevalence of the factor V leiden among patients with ischemic stroke. Haemostasis 1997;27:9-15.
46. Press RD, Liu XY, Beamer N, et al. Ischemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C. Stroke 1996;27:44-8.
47. Catto A, Carter A, Ireland H, et al. Factor V leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscl Thromb Vasc Biol 1995;15:783-5.
48. Tosetto A, Ruggeri M, Castaman G, et al. Inherited abnormalities of blood coagulation in juvenile stroke: a case-control study. Blood Coag Fibrin 1997;8:397-402.
49. Longstreth WT Jr., Rosendaal FR, Siscovick DS, et al. Risk of stroke in young women and two prothrombotic mutations: Factor V leiden and prothrombin gene variant (G20210A). Stroke 1998;29: 577-80.
50. McColl MD, Chalmers EA, Thomas A, et al. Factor V leiden, prothrombin 20210G-A and the MTHFR C677T mutations in childhood stroke. Thromb Haemost 1999;81:690-4.
51. Lalouschek W, Suess E, Aull S, et al. Clinical and laboratory data in heterozygous factor V leiden mutation positive versus negative patients with TIA and minor stroke. Stroke 1995;26:1963-4.
52. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, et al. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997;78:1430-3.
53. De Stefano V, Chiusolo P, Paciaroni K, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998;91:3562-5.
54. Ridker PM, Hennekens CH, Miletich JP, et al. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99:999-1004.
55. Ferraresi P, Marchetti G, Legnani C, et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscl Thromb Vasc Biol 1997;17:2418-22.
56. Corral J, Gonzalez-Conejero RL, Lozano M, et al. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol 1997;99:304-7.
57. Bentolila S, Ripoll L, Drouet L, et al. Thrombophilia due to 20210 G-A prothrombin polymorphism and cerebral ischemia in the young. Stroke 1997;28:1846-7.
58. Cohen SN. Management of Ischemic Stroke. New York: McGraw Hill; 2000.
59. Barnett H, Mohr JP, Stein BM, et al. Stroke: Pathophysiology, Diagnosis, and Management, 3rd ed., Churchill Livingstone; 1998.
60. Welch GN, Upchurch G Jr., Loscalzo J. Hyperhomocyst(e)inemia and atherothrombosis. Ann NY Acad Sci 1997;811:48-59.
61. Boers GH. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost 1997;78:520-2.
62. Caplan LR: Caplan's Stroke: A Clinical Approach, 3rd edn. Boston: Butterworth Heinemann, 2000.
63. Welch KMA, Caplan LR, Reis DJ, et al. Primer on Cerebrovasc Dis, San Diego: Academic Press; 1997.
64. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286-91.
65. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
66. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:1149-55.
67. Lindgren A, Brattstrom L, Norrving B, et al. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995;26: 795-800.
68. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274: 1049-57.
69. Graham IM, Daly LE, Refsum HM. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA 1997;277:1775-81.
70. De Stefano V, Chiusolo P, Paciaroni K, et al. Prothrombin G20210 A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients Blood 1998;91:3562-5.
71. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995;332:328-9.
72. Stampfer MJ, Rimm EB. Folate and cardiovascular disease: why we need a trial now. JAMA 1996;275:1929-30.
73. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for health care professionals from the Stroke Council of the American Heart Association. Stroke 2001;32: 280-99.
74. Chan AK, de Veber G. Prothrombotic disorders and ischemic stroke in children. Sem Ped Neurol 2000;7:301-8.
75. Quattrone A, Colucci M, Donati MB, et al. Stroke in two young siblings with congenital dysfibrinogenemia, It J Neurol Sci 1983;4: 229-32.
76. Lounes KC, Soria C, Mirshahi SS. Fibrinogen Ales: a homozygous case of dysfibrinogenemia (gamma-Asp(330)-Val) characterized by a defective fibrin polymerization site "a". Blood 2000;96: 3473-9.
77. Dolan G, Greaves M, Cooper P, et al. Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds. Br J Haematol 1988;70:417-21.
78. Castaman G, Ruggeri M, Tosetto A, et al. Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation. Am J Hematol 1998;57: 344-7.
79. Ohene-Frempong K, Weiner SJ, Sleeper LA. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91: 288-94.
80. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med 1998; 339:5-11.
81. McCrae KR, Feinstein DI, Cines DB. Antiphospholipid antibodies and the antiphospholipid syndrome. In: Colman RW, Hirsh J, Marder VJ, et al. eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 4th edn. Philadelphia: Lippincott Williams & Wilkins; 2001;1339-56.
82. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952;31:621-2.
83. Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618-25.
84. Levine SR, Deegan MJ, Futrell N, et al. Cerebrovascular and neurologic disease associated with antiphopholipid antibodies: 48 cases. Neurology 1990;40:1181-9.
85. Triplett DA. Many faces of lupus anticoagulants. Lupus 1998;7 (suppl 2):S18-22.
86. Levine SR, Brey RL. Clinical Approach to Antiphospholipid Antibodies. Boston: Butterworth-Heinemann; 2000.
87. Hankey GJ, Warlow CP. Transient Ischemic Attacks of the Brain and Eye. London: WB. Saunders; 1994.
88. Levine SR, Brey RL, Sawaya KL, et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann of Neurol 1995;38:119-24.
89. Feldmann E, Levine SR. Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms, significance, and therapeutic options. Ann Neurol 1995;37:S114.
90. Manoussakis MN, Tzioufas AG, Silis MP, et al. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987;69:557-65.
91. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Int Med 1992;117:303-8.
92. Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thromboocclusive events and death. A prospective cohort study. Stroke 1997;28:1660-5.
93. Antiphospholipid Antibodies in Stroke Study Group (APASS). Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology 1998;47:91-4.
94. Hess DC, Krauss J, Adams RJ, et al. Anticardiolipin antibodies: a study of frequency in TIA and stroke. Neurology 1991;41:525-8.
95. Antiphospholipid antibodies in stroke study group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke 1990;21:1268-73.
96. Tietjen GE, Day M, Norris L, et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study, Neurology 1998;50:1433-40.
97. Levine SR, Brey RL, Joseph CL, et al. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. Stroke 1992;23(suppl 2):I 29-32.
98. The Antiphospholipid Antibodies in Stroke Study Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993;43:2069-73.
99. Montalban J, Codina A, Ordi J, et al. Antiphospholipid antibodies in cerebral ischemia, Stroke 1991;22:750-3.
100. Brey RL, Hart RG, Sherman DG, et al. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990;40:1190-6.
101. Trimble M, Bell DA, Brien W, et al. The antiphospholipid syndrome: prevalence among patients with stroke and transient ischemic attacks. Am J Med 1990;88:593-7.
102. Czlonkowska A, Meurer M, Palasik W, et al. Anticardiolipin antibodies, a disease marker for ischemic cerebrovascular events in a younger patient population? Acta Neurol Scand 1992;86:304-7.
103. Nencini P, Baruffi MC, Abbate R, et al. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992;23:189-93.
104. Nagaraja D, Christopher R, Manjari T. Anticardiolipin antibodies in ischemic stroke in the young: Indian experience. J Neurol Sci 1997; 150:137-42.
105. Roach ES, Riela AR. Traumatic cerebrovascular disorders. In: Pediatric Cerebrovascular Disorders, 2nd ed. Armonk: Futura Publishing Company, Inc.; 1995:291-312.
106. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Int Med 1992;117:997-1002.
107. Metz LM, Edworthy S, Mydlarski R, et al. The frequency of phospholipid antibodies in an unselected stroke population Can J Neurol Sci 1998;25:64-9.
108. Muir KW, Squire IB, Alwan W, et al. Anticardiolipin antibodies in an unselected stroke population. Lancet 1994;344:452-6.
109. Tuhrim S, Rand J, Wu XX, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999;30:1561-5.
110. D'Olhaberriague L, Tanne D, Levine SR, et al. IgG anticardiolipin antibodies: a risk factor for cardiovascular diseases as well as for stroke. Neurology 1998;50:A154.
111. Tanne D, D'Olhaberriague L, Schultz LR, et al. Anticardiolipin antibodies and their associations with cerebrovascular risk factors. Neurology 1999;52:1368-73.
112. Fields RA, Toubbeh H, Searles RP, et al. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989;16:623-5.
113. Gorelick PB, Rusinowitz MS, Tiku M, et al. Embolic stroke complicating systemic lupus erythematosus. Arch Neurol 1985;42: 813-5.
114. Levine SR, Langer SL, Albers JW, et al. Sneddon's syndrome: an antiphaspholipid antibody syndrome? Neurology 1988;38:798-800.
115. Kalashnikova LA, Nasonov EL, Kushekbaeva AE, et al. Anticardiolipin antibodies in Sneddon's syndrome. Neurology 1990;40: 464.
116. Schmidt R, Auer-Grumbach P, Fazekas F. Anticardiolipin antibodies in normal subjects. Neuropsychologic correlates and MRI findings. Stroke 1995;26:749-54.
117. Marullo S, Clauvel JP, Intrator L, et al. Lupoid sclerosis with antiphospholipid and antimyelin antibodies. J Rheumatol 1993;20: 747-9.
118. Bushnell C, Siddiqi Z, Morgenlander JC, et al. Use of specialized coagulation testing in the evaluation of patients with acute ischemic stroke. Neurology 2001;56:624-7.